Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 129,308 shares of the biopharmaceutical company's stock after buying an additional 1,130 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.12% of Regeneron Pharmaceuticals worth $92,110,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $435,000. SteelPeak Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 154.8% in the fourth quarter. SteelPeak Wealth LLC now owns 2,823 shares of the biopharmaceutical company's stock worth $2,011,000 after purchasing an additional 1,715 shares during the last quarter. Tamar Securities LLC raised its stake in shares of Regeneron Pharmaceuticals by 31.7% in the fourth quarter. Tamar Securities LLC now owns 20,401 shares of the biopharmaceutical company's stock worth $14,532,000 after purchasing an additional 4,909 shares during the last quarter. Nilsine Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.8% in the fourth quarter. Nilsine Partners LLC now owns 1,006 shares of the biopharmaceutical company's stock worth $717,000 after purchasing an additional 27 shares during the last quarter. Finally, Slow Capital Inc. raised its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Slow Capital Inc. now owns 12,765 shares of the biopharmaceutical company's stock worth $9,093,000 after purchasing an additional 410 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $4.19 during trading on Thursday, reaching $683.08. The stock had a trading volume of 771,262 shares, compared to its average volume of 885,444. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The business has a fifty day moving average price of $723.36 and a 200-day moving average price of $928.61. The stock has a market cap of $75.06 billion, a PE ratio of 16.90, a PEG ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on REGN shares. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday. Finally, BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.